What Is the Role of Dopamine Transporter Imaging in Parkinson Prevention Clinical Trials?

Neurology. 2022 Aug 16;99(7 Suppl 1):61-67. doi: 10.1212/WNL.0000000000200786.

Authors

John Peter Seibyl¹, Phillip Kuo²

Affiliations

¹ From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT. jseibyl@indd.org.
² From the Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT; Department of Radiology (P.K.), University of Arizona, Tucson; and Invicro, LLC (P.K.), New Haven, CT.

PMID: 35970589
DOI: 10.1212/WNL.0000000000200786

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Corpus Striatum / metabolism
Dopamine Plasma Membrane Transport Proteins* / metabolism
Humans
Parkinson Disease* / diagnostic imaging
Parkinson Disease* / drug therapy
Tomography, Emission-Computed, Single-Photon / methods

Substances

Dopamine Plasma Membrane Transport Proteins